Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-27 00:05 | 2025-02-25 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $52.07 | 1,137 | $59,204 | 1,206 | -48.5% |
| 2025-02-21 00:05 | 2025-02-19 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $56.72 | 1,710 | $96,991 | 1,206 | -58.6% |
| 2025-02-08 00:12 | 2025-02-05 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $61.99 | 1,092 | $67,693 | 1,206 | -47.5% |
| 2025-01-31 00:05 | 2025-01-28 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $61.99 | 3,908 | $242,257 | 1,206 | -76.4% |
| 2024-10-02 23:06 | 2024-10-01 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $41.90 | 568 | $23,799 | 1,124 | -33.6% |
| 2024-07-09 23:05 | 2024-07-05 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $45.00 | 545 | $24,525 | 1,033 | -34.5% |
| 2024-03-11 23:08 | 2024-03-07 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $45.00 | 1,634 | $73,530 | 1,400 | -53.9% |
| 2023-11-18 00:06 | 2023-11-15 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $37.70 | 662 | $24,954 | 1,305 | -33.7% |
| 2023-02-04 00:04 | 2023-02-02 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $31.00 | 330 | $10,230 | 675 | -32.8% |
| 2022-10-18 23:01 | 2022-10-14 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $25.47 | 331 | $8,431 | 875 | -27.4% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.